Experimental and clinical studies show that the probucol derivative AGI-1067 prevents vascular growth

Expert Opinion on Investigational Drugs

Volumn 12, Issue 11, 2003, Pages 1855-1859

  Doggrell, Sheila A ^a  

^a Doggrell Biomedical Communications   (New Zealand)

Author keywords

AGI 1067; Atherosclerosis; CART 1; Probucol; Restenosis

Indexed keywords

ANTILIPEMIC AGENT; ANTIOXIDANT; APOLIPOPROTEIN E; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MESSENGER RNA; MONO[4 [[1 [[3,5 BIS(1,1 DIMETHYLETHYL) 4 HYDROXYPHENYL]THIOL 1 METHYLETHYL]THIO] 2,6 BIS(1,1 DIMETHYL)PHENYL]ESTER]BUTANOIC ACID; MONOCYTE CHEMOTACTIC PROTEIN 1; PLACEBO; PROBUCOL; PROBUCOL SUCCINATE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ANIMAL MODEL; ARTICLE; ATHEROSCLEROSIS; BLOOD VESSEL; CELL CULTURE; CLINICAL TRIAL; DIARRHEA; DRUG MECHANISM; DRUG STRUCTURE; FOLLOW UP; HEART ARRHYTHMIA; HUMAN; INFLAMMATION; LIPID DIET; MONKEY; NONHUMAN; OXIDATION REDUCTION STATE; QT INTERVAL; RESTENOSIS; TACHYCARDIA; TISSUE GROWTH; TORSADE DES POINTES; TRANSGENIC MOUSE; TRANSLUMINAL CORONARY ANGIOPLASTY; UPREGULATION;

ANIMALS; ANTICHOLESTEREMIC AGENTS; ANTIOXIDANTS; ARTERIOSCLEROSIS; CLINICAL TRIALS; CORONARY RESTENOSIS; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; HUMANS; PROBUCOL;

EID: 0242643771     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.12.11.1855     Document Type: Article

References (16)

1. SUNDEL CL, SOMERS PK, MENG CQ et al.: AGI-1067: a multifunctional phenolic antioxidant, lipid modulator antiinflammatory and antiatherosclerotic agent. J. Pharmacol. Exp. Ther. (2003) 305:1116-1123.
2. TARDIF JC, GREGOIRE J, SCHWARTZ L et al.: Effects of AGI-1067 and probucol after percutaneous coronary interventions. Circulation (2003) 107:552-558.
3. PARTHASARATHY S, YOUNG SC, WITZTUM JL, PITTMAN RC, STEINBERG D: Probucol inhibits oxidative modification of low density lipoprotein. J. Clin. Invest. (1986) 77:641-644.
4. WALLDIUS G, ERIKSON U, OLSSON AG et al.: The effect of probucol on femoral atherosclerosis: the Probucol Quantitative Regression Swedish Trial (PQRST). Am. J. Cardiol. (1994) 74:875-883.
5. 2b by probucol partly explains the failure of the drug to affect femoral atherosclerosis in subjects with hypercholesterolemia. A Probucol Quantitative Regression Swedish Trial (PQRST) Report. Arterioscler. Thromb. Vasc. Biol. (1995) 15:1049-1056.
6. SAWAYAMA Y, SHIMIZI C, MAEDA N et al.: Effects of probucol and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia. Fukuoka Atherosclerosis Trial (FAST). J. Am. Coll. Cardiol. (2002) 39:610-616.
7. TARDIF JC, COTE G, LESPERANCE J et al.: Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. Multivitamins and Probucol Study Group. N. Engl. J. Med. (1997) 337:365-372.
8. YOKOI H, DAIDA H, KUWABARA Y et al.: Effectiveness of an antioxidant in preventing restenosis after percutaneous transluminal coronary angioplasty; the Probucol Angioplasty Restenosis Trial. J. Am. Coll. Cardiol. (1997) 30:855-862.
9. KLEIN L: QTc-interval prolongation produced by probucol. Arch. Intern. Med. (1981) 141:1102-1103.
10. REINOEHL J, FRANKOVICH D, MACHADO C et al.: Probucol-associated tachyarrhythmic events and QT prolongation: importance of gender. Am. Heart J. (1996) 131:1184-1191.
11. ENGLER MM, ENGLER MB, MALLOY MJ et al.: Antioxidant vitamins C and E improve endothelial function in children with hyperlipidemia: Endothelial Assessment of Risk for Lipids in Youth (EARLY) Trial. Circulation (2003) 108:1059-1063.
12. TEPEL M, VAN DER GIET M, STATZ M, JANKOWSKI J, ZIDEK W: The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: a randomized, controlled trial. Circulation (2003) 107:992-995.
13. TOUSOULIS D, DAVIES G, STEFANADIS C, TOUTOUZAS P, AMBROSE JA: Inflammatory and thrombotic mechanisms in coronary atherosclerosis. Heart (2003) 89:993-997.
14. WELT FG, ROGERS C: Inflammation and restenosis in the stent era. Arterioscler. Throm. Vasc. Biol. (2002) 22:1769-1776.
15. SEMB AG, VAN WISSEN S, UELAND T et al.: Raised serum levels of soluble CD40 ligand in patients with familial hypercholesterolemia: downregulatory effect of statin therapy. J. Am. Coll. Cardiol. (2003) 41:275-279.
16. CHAN AW, BHATT DL, CHEW DP et al.: Relation of inflammation and benefit& of statins after percutaneous coronary interventions. Circulation (2003) 107:1750-1756.